Seeking Alpha
14 Aug 2026, 19:36 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
ProKidney's cash runway extends only into mid-2027 with $181.6M remaining and high burn, raising 'going concern' doubts. — Severe liquidity risk and potential insolvency threats typically lead to significant sell-offs in small-cap biotech.
-0.90Phase 2 data for rilparencel is characterized as weak with no robust evidence of efficacy. — Lack of efficacy in early-stage trials suggests a high probability of failure for the lead asset.
-0.80Pivotal Phase 3 PROACT data for the company's only asset is not expected until 2027. — The long time horizon until a definitive catalyst increases risk and delays potential valuation inflection points.
-0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company faces weak clinical data, high cash burn, and significant doubts regarding its ability to continue as a going concern.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
